Cigarette smoking and competing risks for fatal and nonfatal cardiovascular disease subtypes across the life course

Sadiya S. Khan*, Hongyan Ning, Arjun Sinha, John Wilkins, Norrina B. Allen, Thanh Huyen T. Vu, Jarett D. Berry, Donald M Lloyd-Jones, Ranya Sweis

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

30 Scopus citations

Abstract

BACKGROUND: Cigarette smoking is significantly associated with premature death related and not related to cardiovascular disease (CVD). Whether risk associated with smoking is similar across CVD subtypes and how this translates into years of life lost is not known. METHODS AND RESULTS: We pooled and harmonized individual-level data from 9 population-based cohorts in the United States. All participants were free of clinical CVD at baseline with available data on current smoking status, covariates, and CVD outcomes. We examined the association between smoking status and total CVD and CVD subtypes, including fatal and nonfatal coronary heart disease, stroke, congestive heart failure, and other CVD deaths. We performed (1) modified Kaplan– Meier analysis to estimate long-term risks, (2) adjusted competing Cox models to estimate joint cumulative risks for CVD or noncardiovascular death, and (3) Irwin’s restricted mean to estimate years lived free from and with CVD. Of 106 165 adults, 50.4% were women. Overall long-term risks for CVD events were 46.0% (95% CI, 44.7– 47.3) and 34.7% (95% CI, 33.3– 36.0) in middle-aged men and women, respectively. In middle-aged men who reported smoking compared with those who did not smoke, competing hazard ratios (HRs) were higher for the first presentation being a fatal CVD event (HR, 1.79 [95% CI, 1.68– 1.92]), with a similar pattern among women (HR,1.82 [95% CI, 1.68–1.98]). Smoking was associated with earlier CVD onset by 5.1 and 3.8 years in men and women. Similar patterns were observed in younger and older adults.

Original languageEnglish (US)
Article numbere021751
JournalJournal of the American Heart Association
Volume10
Issue number23
DOIs
StatePublished - Dec 7 2021

Funding

Dr Berry reports personal fees from Astra Zeneca, personal fees from the Cooper Institute, grants from Abbott, and grants and personal fees from Roche outside the submitted work. Dr Allen reports grants from the National Institutes of Health and grants from the American Heart Association outside the submitted work. The remaining authors have no disclosures to report. This work was supported by grants from the National Institutes of Health/ National Heart, Lung, and Blood Institute to Dr Lloyd-Jones (R21 HL085375). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Dr Khan is supported by grants from the National Institutes of Health/National Heart, Lung, and Blood Institute (KL2TR001424, P30AG059988, P30DK092939, R01HL159250) and the American Heart Association (19TPA34890060). The research reported in this publication was supported in part by the National Institutes of Health’s National Center for Advancing Translational Sciences, Grant Number KL2TR001424 (Dr Khan).

Keywords

  • Cardiovascular disease
  • Cardiovascular mortality
  • Smoking

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Cigarette smoking and competing risks for fatal and nonfatal cardiovascular disease subtypes across the life course'. Together they form a unique fingerprint.

Cite this